First Allied Advisory Services Inc. Sells 126,655 Shares of GlaxoSmithKline plc (GSK)

First Allied Advisory Services Inc. cut its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 70.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 53,023 shares of the pharmaceutical company’s stock after selling 126,655 shares during the period. First Allied Advisory Services Inc.’s holdings in GlaxoSmithKline were worth $1,883,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Advisory Services Network LLC increased its position in shares of GlaxoSmithKline by 24.2% during the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after acquiring an additional 788 shares in the last quarter. Shufro Rose & Co. LLC increased its position in shares of GlaxoSmithKline by 20.7% during the third quarter. Shufro Rose & Co. LLC now owns 8,750 shares of the pharmaceutical company’s stock worth $355,000 after acquiring an additional 1,500 shares in the last quarter. HighPoint Advisor Group LLC increased its position in shares of GlaxoSmithKline by 10.0% during the third quarter. HighPoint Advisor Group LLC now owns 16,735 shares of the pharmaceutical company’s stock worth $602,000 after acquiring an additional 1,522 shares in the last quarter. Pinkerton Retirement Specialists LLC increased its position in shares of GlaxoSmithKline by 2.7% during the third quarter. Pinkerton Retirement Specialists LLC now owns 59,426 shares of the pharmaceutical company’s stock worth $2,433,000 after acquiring an additional 1,578 shares in the last quarter. Finally, Financial Advisory Service Inc. increased its position in shares of GlaxoSmithKline by 10.7% during the third quarter. Financial Advisory Service Inc. now owns 16,980 shares of the pharmaceutical company’s stock worth $689,000 after acquiring an additional 1,639 shares in the last quarter. 9.17% of the stock is owned by institutional investors.

Several equities research analysts have recently commented on GSK shares. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 24th. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Bank of America cut shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. TheStreet upgraded shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Finally, Investec cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $38.97.

Shares of GlaxoSmithKline plc (NYSE GSK) opened at $37.70 on Monday. The company has a market cap of $93,461.99, a P/E ratio of 13.05, a P/E/G ratio of 2.37 and a beta of 0.98. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. GlaxoSmithKline plc has a 52 week low of $34.52 and a 52 week high of $44.53.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.03. The company had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. research analysts predict that GlaxoSmithKline plc will post 2.85 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Friday, February 23rd will be paid a dividend of $0.633 per share. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.72%. The ex-dividend date is Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio is presently 258.23%.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/19/first-allied-advisory-services-inc-sells-126655-shares-of-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply